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Background: Women presenting with reduced fetal movements (RFM) in the third trimester are at increased risk of
stillbirth or fetal growth restriction. These outcomes after RFM are related to smaller fetal size on ultrasound scan,
oligohydramnios and lower human placental lactogen (hPL) in maternal serum. We performed this study to address
whether a randomised controlled trial (RCT) of the management of RFM was feasible with regard to: i) maternal
recruitment and retention ii) patient acceptability, iii) adherence to protocol. Additionally, we aimed to confirm the
prevalence of poor perinatal outcomes defined as: stillbirth, birthweight <10th centile, umbilical arterial pH <7.1 or
unexpected admission to the neonatal intensive care unit.
Methods: Women with RFM ≥36 weeks gestation were invited to participate in a RCT comparing standard
management (ultrasound scan if indicated, induction of labour (IOL) based on consultant decision) with intensive
management (ultrasound scan, maternal serum hPL, IOL if either result was abnormal). Anxiety was assessed by
state-trait anxiety index (STAI) before and after investigations for RFM. Rates of protocol compliance and IOL for
RFM were calculated. Participant views were assessed by questionnaires.
Results: 137 women were approached, 120 (88%) participated, 60 in each group, 2 women in the standard group
did not complete the study. 20% of participants had a poor perinatal outcome. All women in the intensive group
had ultrasound assessment of fetal size and liquor volume vs. 97% in the standard group. 50% of the intensive
group had IOL for abnormal scan or low hPL after RFM vs. 26% of controls (p < 0.01). STAI reduced for all women
after investigations, but this reduction was greater in the standard group (p = 0.02). Participants had positive views
about their involvement in the study.
Conclusion: An RCT of management of RFM is feasible with a low rate of attrition. Investigations decrease maternal
anxiety. Participants in the intensive group were more likely to have IOL for RFM. Further work is required to
determine the likely level of intervention in the standard care arm in multiple centres, to develop additional
placental biomarkers and to confirm that the composite outcome is valid.
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Reduced fetal movements (RFM) is a frequently seen
problem in maternity care with 6–15% of women
reporting attending at least one occasion of RFM to health
professionals in the third trimester of pregnancy [1,2].
RFM, defined by maternal perception of significantly re-
duced or absent fetal activity, is associated with increased
risk of stillbirth and fetal growth restriction (FGR) due to
placental dysfunction [3,4]. Despite this association there
is a paucity of evidence to direct clinical management of
women presenting with RFM. This has been recently
highlighted by guidelines from the Royal College of Ob-
stetrics and Gynaecology (RCOG) and a meta-analysis,
where the highest level of evidence identified was level 2
(case-control study) [5-7]. The absence of high-quality evi-
dence has led to wide variation in management strategies
for RFM in high-income settings [8,9].
Cohort studies carried out on different populations have
found that the investigations that best predicted poor peri-
natal outcome (including stillbirth, FGR and admission to
the neonatal intensive care unit (NICU)) after RFM were
electronic fetal monitoring, ultrasound assessment of fetal
weight and liquor volume and measurement of human
placental lactogen (hPL) in maternal serum [6,10]. Al-
though there are randomised controlled trials (RCT) of
counting fetal movements by a formal structure (e.g. count
to ten [11,12]) there have been no published RCTs of pa-
tient management following presentation with RFM [7].
To undertake an RCT of patient management raises im-
portant practical concerns including: maternal anxiety for
fetal wellbeing, the need to make a decision regarding par-
ticipation in a short period of time due to the acute nature
of RFM and adherence to protocol. Thus, studies have
adopted an approach of changing practice at the unit level
in quality-improvement projects [6] or stepwise cluster
RCT (AFFIRM, NCT01777022 [13]).
We performed this study to address whether an RCT
of the management of RFM in individual patients was an
appropriate trial design, and was feasible with regard to
i) maternal recruitment and retention ii) patient accept-
ability, iii) adherence to protocol. In addition, we wished
to confirm the prevalence of poor perinatal outcomes in
the study population.
Methods
Women attending a single maternity unit (St Mary’s Hos-
pital, Manchester, UK) presenting with RFM after 36 weeks
gestation between October 2011 and August 2012 were
invited to participate. The protocol was given a favourable
ethical opinion by the Greater Manchester North Research
Ethics Committee (11/NW/0664) and was registered on
the International Standard Randomised Controlled Trial
Number Register (ISRCTN07944306). Women were ex-
cluded if there was a known congenital anomaly, multiplepregnancy, the fetus required immediate delivery for ab-
normal fetal heart rate trace, maternal age was less than
16 years or they were unable to give informed consent.
Recruitment
Women meeting the inclusion criteria were approached
by the research midwife (GB) either during their attend-
ance at the maternity day unit (MDU) if between 9 am–
5 pm or on the morning after attending the obstetric tri-
age service outside normal hours (5 pm–9 am). Women
approached during attendance at MDU were given infor-
mation during the initial fetal heart rate assessment which
lasted approximately 45 minutes. Women were then
randomised to standard or intensive management groups
by computer, using individual randomisation in a 1:1 ratio
with random variable block size. This was facilitated by
the University of Nottingham Clinical Trials Unit. We
aimed to randomise 120 patients in total, giving 60 pa-
tients in each arm of the study. From our previous studies
we anticipated a loss to follow-up of <5% (3 participants
per arm) and estimated that 150 women would need to be
approached to recruit 120 participants. In addition, demo-
graphic data were collected on non-participants to deter-
mine whether there were differences between participants
and non-participants.
Intervention
Women assigned to intensive management had an ultra-
sound scan to measure head circumference, abdominal cir-
cumference and femur length, liquor volume and umbilical
artery Doppler. Estimated fetal weight (EFW) was calcu-
lated using the Hadlock B formula [14]. hPL was measured
in maternal serum by enzyme-linked immunoassay of sam-
ples in triplicate (Immunodiagnostic systems, Boldon, UK).
Low hPL for gestation was defined as <0.8 MoM. If any of
the investigations were abnormal, obstetricians caring for
women in the intensive group were recommended to ex-
pedite delivery by the most appropriate method, usually in-
duction of labour unless there was an indication for
Caesarean delivery. Women in the standard group had as-
sessment of EFW, liquor volume and umbilical artery Dop-
pler if they met the unit criteria for ultrasound scan which
were: two or more attendances with RFM or more than 37
completed weeks’ gestation or symphysiofundal height
below the tenth centile. The results of these investigations
were discussed with the obstetrician caring for the woman
who made an independent decision regarding subsequent
management.
Participant outcome
All outcome data for trial analysis were obtained from the
clinical notes. Data were collected on trial-specific case re-
port forms according to a standard operating procedure
and entered into a Microsoft Access database by the
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random were checked for accuracy by a second investiga-
tor (AH). Poor pregnancy outcome was defined as still-
birth, small for gestational age infant defined as an
individualised birthweight centile <10th, umbilical arterial
pH <7.1 or unexpected admission to NICU. These out-
comes were chosen as previous studies have shown that
infants stillborn after RFM were SGA [15], and infants
subject to severe intra-uterine compromise might not die
but instead require neonatal intensive care [16]. Data re-
garding levels of maternal anxiety were obtained before
and after the investigations by the state-trait anxiety index
(STAI) which has previously been validated in pregnancy.
Specifically-designed questionnaires were designed to as-
sess women’s and clinician’s experiences of trial proce-
dures. The women’s questionnaire contained scales to
rank responses to statements about participation in the
trial, two closed questions and a free-text box for further
comments. The questionnaire was piloted with five
women and responses checked for clarity and content val-
idity. The questionnaire for clinicians assessed their aware-
ness of the trial with closed questions and their opinions












Figure 1 Flow diagram of the trial process.responses. The questionnaires were administered after
women had given birth and in the case of clinicians after
the feasibility study had been completed. STAI and ques-
tionnaire responses were collated in Microsoft Excel.
Analysis
Participant demographics, adherence to protocol and par-
ticipant questionnaires were analysed descriptively in ac-
cordance with published recommendations for analysis of
pilot studies [17]. State anxiety scores before and after in-
vestigations were compared using Wilcoxon signed rank
test; trait anxiety scores and changes in state scores were
compared between groups using Mann-Whitney U tests.
All analyses were conducted using SPSS version 16.0
(SPSS Inc, IL, USA), a p-value of <0.05 was considered to
be statistically significant in all analyses.
Results
Participant recruitment and retention
One hundred and thirty seven women were approached to
participate in the study between December 2011 and
August 2012 (Figure 1). One hundred and twenty (87.5%)
agreed and 60 were randomised to each arm. Womenmen 
hed
17 declined to participate
• Declined blood test
• Did not wish to give placenta to research
• Unwilling to decide whether to participate
at this attendance
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demographic characteristics to participants except for a
higher proportion of women of Black African ethnicity in
non-participants (Table 1). However, women participating
in this study had similar demographic characteristics to
the whole unit population. This was also the case in a pre-
vious cohort study carried out in the same institution [10].
Two patients (1.7%) withdrew from the study, both of
whom were in the standard treatment arm; these women
cited pressure from partners not to participate as motivat-
ing their decision to withdraw from the study.
Participant acceptability
There was no difference in the anxiety score before investi-
gations between women assigned to the control or intensive
management groups (Figure 2A). Women in both groups
experienced a reduction in state anxiety after investigations
(Figure 2B); this reduction in state anxiety was greater in
women in the control group (Figure 2C). This may either
be a chance finding or could be attributed to the increased
detection of abnormalities requiring intervention in the in-
tensive management group. Eighty-three participants (69%)
responded to the end of study questionnaire given after the
birth of their child; 44 (53%) of respondents received stand-
ard care and 39 (47%) of respondents received intensive
management. All participants felt that the time at which
they were approached to participate was acceptable
(Table 2); 99% and 98% of participants felt they had suffi-
cient information and time to make a decision to partici-
pate respectively. All patients understood the patient
information and consent form. The majority of participants
did not mind which group they were assigned to, althoughTable 1 Demographic characteristics of study participants com
in a previous cohort study in the same centre
Characteristic Participants (n = 120) Non-consen
Age 28 (18–42) 27 (1
BMI 25 (18–50) 26 (1
Gravidity 2 (1–9) 2(1
Parity 1 (0–5) 0 (0
Ethnicity
Bangladeshi 6 (5%) 1 (
Black African 8 (7%) 7 (4
Black Caribbean 3 (3%) 1 (
Indian 4 (3%) 3 (1
Pakistani 19 (16%) 1 (
White European 74 (62%) 2 (1
Other ethnic groups 6 (5%) 2(1
Cigarette Smoker 12 (10%) Unkn
Gestation at Presentation 38+6 (36+0–41+1) 38+4 (36
For continuous variables the median is shown with the range in parentheses, for ca
parentheses. *Denominator for ethnicity in unit population = 6,865. †Denominator f6 (7%) expressed a clear preference to enter the interven-
tion arm. Eighty-one (98%) participants felt that the num-
ber of tests to establish fetal wellbeing was satisfactory; the
remaining two participants would have liked more tests,
these participants were both in the standard management
group. Seventy-seven (93%) of respondents felt the results
were given in a timely manner. Overall, 98% of participants
would recommend the study to a friend whose baby was
moving less.
Protocol adherence and professionals’ views
All patients in the intensive management arm had an
ultrasound assessment of fetal growth, liquor volume and
umbilical artery Doppler as compared to 97% in the con-
trol group. All women in the intensive group had hPL
measured in maternal serum compared to no patients in
the control group (Table 3). Ultrasound scans showed re-
duced fetal growth, oligohydramnios or abnormal umbil-
ical artery Doppler in 14% of cases, 20% of the intensive
group and 8% of the control group; as randomisation oc-
curred before the ultrasound scan was performed this dis-
crepancy must be due to chance. hPL was <0.8 MoM in
30% of women in the intensive management group. Over-
all, the frequency of induction of labour (IOL) was no dif-
ferent between groups (Table 3); 59% in control compared
to 62% in intensive management group. However, the pro-
portion of women being induced for RFM was higher in
the intensive management group 50% vs. 26%. In the con-
trol group the majority of IOL were for prolonged rupture
of membranes or prolonged pregnancy. There was no dif-
ference in gestational age at presentation or at delivery.
There was no increase in instrumental or Caesarean birthpared to those would did not consent and participants
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Figure 2 State-trait anxiety scores for participants (n = 120). A) There was no difference in the trait score between participants randomised
to the control or intensive management protocol. B) Maternal state anxiety was significantly reduced in both control and intensive management
groups after completion of the investigations (** p < 0.01). C) The reduction in state anxiety was greatest in the women in the control group
(* p < 0.05).
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20% of women had a poor perinatal outcome, with the
most frequent outcome being birthweight <10th centile;
there were no stillbirths in either group. Although the
study was not powered to detect differences in outcomes,
and no formal hypothesis tests were planned; there were
fewer poor perinatal outcomes in the intensive manage-
ment group. It is interesting that the increased number of
abnormalities on the ultrasound scan observed in the in-
tensive group did not translate into increased poor preg-
nancy outcomes.
Eight consultant obstetricians and seven experienced
midwives from the maternity day unit, maternity triage
and delivery unit responded to the staff questionnaire
(Table 5). Fourteen staff (93%) were confident in which in-
vestigations to use and 87% confident when to expedite de-
livery when caring for women with RFM. However, only
33% felt that care of women with RFM is currently based
on grade 1/2 evidence. All staff were aware that the study
had taken place, 87% were aware that women in their carehad participated in the study and 73% were aware of the
recommended management plan. Ten (67%) of profes-
sionals felt that results were given in a timely manner, 60%
felt that the results of the investigations for patients in the
intensive group altered their management with 27% per-
ceiving an increase in labour interventions. Twenty percent
of professionals felt that the study increased workload to
the antenatal service, but the majority (47%) disagreed with
this statement. All professionals would offer participation
in this trial to a woman presenting with RFM.
Discussion
A recent systematic review and meta-analysis and the
RCOG guideline have identified the need for robust evi-
dence to guide the management of RFM [5,7]. This feasi-
bility study suggests that a randomised controlled trial of
the individualised management of RFM would be accept-
able to women perceiving RFM after 36 weeks gestation
and to professionals, given a participation rate of 87% and
a dropout rate of <2%. A minority of participants were
Table 2 Responses from participants to the end of study questionnaire administered after delivery (n = 83)
Statement/Question Strongly agree Agree Unsure Disagree Strongly disagree Not answered
The time I was first approached to participate in
the trial was acceptable
52 (63) 31 (37) 0 (0) 0 (0) 0 (0) 0 (0)
I had sufficient information to make a decision to
participate in the trial
56 (67) 26 (31) 1 (1) 0 (0) 0 (0) 0 (0)
I had sufficient time to make a decision to
participate in the trial
46 (55) 33 (40) 1 (1) 1 (1) 0 (0) 2 (2)
I understood the information I was given 52 (63) 31 (37) 0 (0) 0 (0) 0 (0) 0 (0)
The consent form was clear 53 (64) 30 (36) 0 (0) 0 (0) 0 (0) 0 (0)
I did not mind which group (standard management
or intensive testing) I was assigned to
36 (43) 34 (41) 6 (7) 6 (7) 0 (0) 1 (1)
The amount of tests I had was satisfactory 45 (54) 34 (41) 0 (0) 2 (2) 0 (0) 2 (2)
The results of the tests were given within
an appropriate time period
50 (60) 27 (33) 4 (5) 0 (0) 0 (0) 2 (2)
Yes Unsure No Not answered
Would you recommend participating in the
trial to a friend who noticed her baby was moving less
81 (97.6) 2 (2.4) 0 (0) 0 (0)
Figures in parentheses denote percentages of respondents.
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but this did not appear to cause participants to withdraw
from the standard arm of the trial. These effects of partici-
pant preference are similar to those previously described in
other analyses of randomised controlled trials [18,19]. Im-
portantly, both strategies tested here resulted in a decrease
in maternal anxiety after tests were performed, but the re-
duction in anxiety was greater in women receiving standardTable 3 Protocol compliance as assessed by proportion of wo
Intervention Contr
Ultrasound Scan 58
Abnormal EFW, LV or UAD 5
hPL 0









Prolonged rupture of membranes 10
Small for gestational age 2
Suspicious cardiotocograph on subsequent presentation 1
Gestation at Delivery 40+1 (3
Delivery by CS 8
Instrumental Delivery 11
Absolute values are shown with percentages in parentheses. † = Denominator value
intensive arm all had either abnormal scan findings or low hPL.management compared to intensive management group.
This may reflect concerns of women who had an abnormal
investigation leading to IOL which was more frequent in
the intensive management group. This feasibility study sug-
gests that a larger trial may increase the rate of IOL for
RFM as a primary intervention for abnormal investigation
findings, but this should not impact on instrumental or
Caesarean delivery. This is in agreement with studies thatmen having investigations and induction of labour (IOL)
ol (n = 60) Intensive (n = 60) Total (n = 120)
(97%) 60 (100%) 118 (98%)
(8%) 12 (20%) 17 (14%)
(0%) 60 (100%) 60 (50%)
- 18 (30%) 18 (15%)
ol (n = 58) Intensive (n = 60) Total (n = 118)
(59%)† 37 (62%) 71 (60%)
(26%)† 30 (50%)‡ 45 (38%)
(2%) 1 (2%) 2 (2%)
0 1 (2%) 1 (1%)
(2%) 0 1 (1%)
(7%) 2 (3%) 6 (5%)
(17%) 3 (5%) 13 (11%)
(3%) 0 2 (2%)
(2%) 0 1 (1%)
7+0–42+1) 39+6 (36+4–42+0) 40+0 (36+4–42+1)
(14%)† 4 (7%) 12 (10%)
(19%)† 15 (25%) 26 (22%)
of 58 (as two outcomes unknown). ‡ The 30 women induced for RFM in the








Poor Pregnancy Outcome 17 (29%)†* 7 (12%)* 24 (20%)
Primary 6 (10%)† 2 (3%) 8 (7%)
Stillbirth 0 (0) 0 (0) 0 (0)
Unexpected Admission to NICU 3 (5%)† 1 (2%) 4 (3%)
Metabolic acidosis (art pH ≤7.1) 3 (5%)† 1 (2%) 4 (3%)
Secondary
Birthweight≤ 10th centile 11 (19%)† 5 (8%) 16 (14%)
* Intensive vs. Control p = 0.022 (Fisher’s Exact test).
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of fetal movement counting or in quality improvement
studies for women with RFM [20,21].
Clinicians in this single tertiary centre were confident in
their current management of RFM, but 66% recognised that
their management strategies were not based on robust evi-
dence. Studies of the management of RFM in UK and
Australia highlighted variation in individuals’ management
of RFM and that a large proportion of respondents would
be willing to participate in a trial of fetal movement
counting or management of RFM [8,9]. However, almostTable 5 Responses from obstetricians and midwives to the qu
(n = 15)
Statement/Question
I am confident which investigations to use when caring for women with
RFM
I am confident when to intervene (expedite delivery) when caring
for women with RFM at term
The care of women (clinical and supportive management) with RFM
is currently based on robust evidence (Grade 1 or 2).
The results of the investigations were given to women and the medical
team in an appropriate time period
The findings of the investigations (ultrasound scan and human
placental lactogen) in the ReMIT study altered my
management of women with RFM
I appeared that participation in the ReMIT study
increased anxiety in the participants
In my opinion the ReMIT study increased labour interventions
(e.g. induction of labour, Caesarean section)
The ReMIT study led to a significant increase in the workload
to the antenatal triage, maternity day unit and delivery suite
Were you aware that the ReMIT study was taking place in
St Mary’s Hospital?
Were any of the women in your care participants in the ReMIT study?
Were you aware of the recommended management plan
for the women in the intensive arm of the ReMIT study?
Would you be happy to offer participation in this trial to
a woman who noticed her baby was moving less
Figures in parentheses denote percentages of respondents.all of the participants in this clinical trial underwent ultra-
sound to assess fetal growth and liquor volume irrespective
of the group they were assigned to. We suspect that this re-
flects the local practice within our tertiary unit, where there
is an interest in using RFM to identify compromised fe-
tuses, as surveys in the UK and Australia found that
18.6%–20.2% of obstetricians routinely carried out ultra-
sound assessment of fetal growth. A recent survey of guide-
lines for the management of RFM in obstetric units
(Whitworth et al. unpublished data) has found that a mi-
nority of local guidelines (33%) recommend ultrasound
scan as a routine investigation for RFM. Prior to commen-
cing a larger multi-centre study, clinical practice should be
re-evaluated to determine standard management of RFM
and the equipoise of practitioners regarding the investiga-
tions and management of women presenting with RFM.
This feasibility study found that some patients, particu-
larly those of Black African ethnicity were more likely to
decline participation. It is difficult to draw firm conclusions
due to small numbers in this study, but this needs to be in-
vestigated further to determine whether members of mi-
nority ethnic groups would be less likely to participate in a
trial of the management of RFM and if so, the reasons
underlying their decision. Although participants felt that
the trial documentation was clear, this may need to beestionnaire administered after completion of the study
Strongly agree Agree Unsure Disagree Strongly disagree
6 (40) 8 (53) 0 (0) 1 (7) 0 (0)
6 (40) 7 (47) 1 (7) 1 (7) 0 (0)
2 (13) 3 (20) 2 (13) 6 (40) 2 (13)
3 (20) 7 (47) 5 (33) 0 (0) 0 (0)
3 (20) 6 (40) 6 (40) 0 (0) 0 (0)
0 (0) 1 (7) 3 (20) 9 (60) 2 (13)
1 (7) 3 (20) 8 (53) 2 (13) 1 (7)
2 (13) 1 (7) 5 (33) 6 (40) 1 (7)
Yes Unsure No
15 (100) 0 (0) 0 (0)
13 (86.7) 0 (0) 2 (13.3)
11 (73.3) 0 (0) 4 (26.7)
15 (100) 0 (0) 0 (0)
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possible. Furthermore, participants could be reassured
there was no increased obstetric interventions in partici-
pants in the intensive arm of the trial and that few patients
discontinued the trial.
This study confirmed evidence from prospective and
retrospective cohort studies [10,15] that approximately
20% of women presenting with RFM will have a poor
pregnancy outcome, defined here as a composite of: birth-
weight <10th centile on a customised birthweight chart,
unexpected admission to NICU or umbilical arterial pH
<7.1. There were no stillbirths or neonatal deaths in this
small RCT as would be expected given the sample size
(the background incidence of stillbirth in this institution is
6.9/1,000 live births). This observation raises two related
questions with regard to the sample size of a definitive
trial: i) the use of a composite outcome and ii) the subse-
quent formulation of the question to be addressed.
Due to the relative infrequency of stillbirth, currently
5.2/1,000 live births in the UK, studies frequently use a
composite outcome. For example the composite out-
come used in the DIGITAT study, a randomised con-
trolled trial comparing induction of labour to expectant
management for intrauterine growth restriction near
term, was: death before hospital discharge, five minute
Apgar score of less than 7, umbilical artery pH of less
than 7.05, or admission to neonatal intensive care [22].
However, other studies of groups at high-risk of peri-
natal mortality, such as severe FGR have used death be-
fore 2 years of age e.g. the GRIT study [23]. The use of
composite end points in RCTs is controversial; they are
used to reduce sample size requirements and capture
the overall impact of an intervention [24], but they may
exaggerate the effect of an intervention, particularly
where one component of the composite outcome, which
may be less biologically relevant, shows a significant ef-
fect [25]. It is essential that a composite outcome con-
tains outcomes important to patients and the magnitude
of effect is maintained across different individual end-
points within the composite outcome [26]. Our prelim-
inary data suggest that the composite “poor perinatal
outcome” used in this study: stillbirth, small for gesta-
tional age infant defined as an individualised birthweight
centile <10th, umbilical arterial pH <7.1 or unexpected
admission to the neonatal intensive care unit, encom-
passes the spectrum of morbidity and mortality associ-
ated with RFM, which may result from the relationship
between RFM and placental insufficiency. The most fre-
quent endpoint is birthweight <10th centile which was a
secondary outcome in this feasibility study. However, in
this study 7% of patients had a poor primary outcome
including acidosis or admission to NICU. Prior to a de-
finitive trial further work on composite outcomes is re-
quired to address whether the effect is maintainedacross different individual endpoints within the compos-
ite outcome.
The formulation of the question to be addressed is also
critical to determine sample size. Alternatives to individual
management include a cluster-randomsied or stepped-
wedge design. Here the choice to participate is removed
from the individual, but this design may address relevant
confounding effects in the management of RFM e.g. a high
proportion of the standard group had an ultrasound scan.
However, one drawback of such studies is the need for
greater numbers of participants. An alternative strategy
proposed to reduce the sample size required for a definitive
RCT of the management of RFM is to alter the question
being posed and randomise to intervention after having a
screening test [27]. In this context, women determined to
be high-risk for poor perinatal outcome after RFM would
be randomised to intervention (delivery) or conservative
management. While this study has demonstrated that
women presenting with RFM and the clinicians caring for
them will accept an RCT randomising them to intensive or
standard investigations, a further feasibility study would be
necessary to determine whether randomisation after a test
designating participants to be at high-risk of complications
would be feasible. As women in the intensive arm already
experienced greater anxiety than women receiving stand-
ard care, it could be speculated that delaying intervention
after highlighting an increased risk of morbidity would
raise maternal anxiety to unacceptable levels.
To determine sample size of a definitive trial the follow-
ing assumptions have been made: i) 33% of stillbirths
occur after 36 weeks gestation [28]; ii) the risk of stillbirth
after RFM is three-times greater than the background risk;
iii) 20% of pregnancies with RFM end in poor pregnancy
outcome. To detect a 20% reduction in stillbirths after
36 weeks gestation with a power of 80% and α = 0.05
would require 146,945 patients per arm, if this is extended
to death before discharge, 128,457 patients per arm are re-
quired. To use the approach of randomisation after testing
conservatively assumes that women with a positive test
are at a four-fold increased risk of poor perinatal outcome.
To demonstrate a 20% reduction in perinatal mortality
would require 5,568 participants in each arm, as 50% of
women test positive, 22,272 women would need to be
approached and tested. In comparison, to observe a reduc-
tion in composite poor perinatal outcome from 20% of
women presenting with RFM after 36 weeks gestation to
16% would require 1,447 participants in each arm. Using
the randomisation after testing approach in combination
with the measure of poor perinatal outcome would reduce
this further to 270 participants per arm, meaning that
1,080 participants would be required. There are approxi-
mately 700,000 births in England and Wales per year [29],
and assuming 6% of women are reported to attend on at
least one occasion with RFM [1], there are estimated to be
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of pregnancy. If 33% of these are over 36 weeks gestation,
this leaves approximately 14,000 women who may be eli-
gible for a multi-centre study. This makes a study with
stillbirth as the sole primary outcome unfeasible. However,
using a composite primary outcome or randomisation
after testing approach appropriate recruitment would be
achievable. The feasibility study carried out here suggests
that the former would be acceptable to patients and pro-
fessionals. However, additional measures may be required
to reduce maternal anxiety due to abnormal investigations
the intensive group; these could include verbal and written
information provided by staff.
Conclusion
This feasibility study demonstrates that an individual
randomised controlled trial of the management of RFM is
feasible in a diverse group women perceiving RFM after
36 weeks gestation. Investigations decrease maternal anx-
iety. Participants in the intensive group were more likely
to have IOL for RFM although the overall rates were simi-
lar. Professionals described the need for better evidence
on which to base practice and were willing to adapt their
management strategies to the trial protocol. Further stud-
ies are required to determine the likely level of interven-
tion in the standard care arm in multiple centres, to
develop additional placental biomarkers and to confirm
that the composite outcome is valid.
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